Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5

BACKGROUND: N8‐GP (turoctocog alfa pegol; Esperoct(®), Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated, extended half‐life human recombinant factor VIII (FVIII). OBJECTIVE: Here, we report end‐of‐trial safety and efficacy results from the completed N8‐GP pathfinder5 trial. METHODS: pathfin...

Descripción completa

Detalles Bibliográficos
Autores principales: Šaulytė Trakymienė, Sonata, Economou, Marina, Kenet, Gili, Landorph, Andrea, Shen, Chunduo, Kearney, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540298/
https://www.ncbi.nlm.nih.gov/pubmed/32940955
http://dx.doi.org/10.1111/jth.15036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540298/
https://www.ncbi.nlm.nih.gov/pubmed/32940955
http://dx.doi.org/10.1111/jth.15036

Ejemplares similares